Demographic data from the selected matched cohort.

<p>SAPS II - Simplified Acute Physiology Score; ICU – Intensive Care Unit; NFGNB – Non-fermenting Gram-negative bacteria.</p><p>Data presented as mean ± standard deviation or N (percentage).</p>*<p>McNemar’s test;</p>**<p>Paired Student’s <i>t</i> test.</p

Cumulative mortality in the first 28 days after starting piperacillin/tazobactam therapy either in continuous infusion (dashed line) or 30 min bolus dosing (solid line).

<p>Cumulative mortality in the first 28 days after starting piperacillin/tazobactam therapy either in continuous infusion (dashed line) or 30 min bolus dosing (solid line).</p

Outcomes of patients treated with piperacillin/tazobactam, either as continuous infusion or intermittent dosing.

1<p>Patients discharged from ICU;</p>2<p>Patients discharged from hospital.</p><p>ICU – Intensive Care Unit; SAPS - Simplified Acute Physiology Score.</p><p>Data presented as percentage or median [Interquartile Range].</p>*<p>McNemar’s test;</p>**<p>Mann Whitney <i>U</i> test;</p>#<p>Chi Square test.</p

Main microorganisms isolated.

<p>All included microorganisms had <i>in vitro</i> susceptibility to piperacillin/tazobactam.</p><p>NFGNB – Non-fermenting Gram-negative bacteria.</p

Sub-group analyses of 28-day mortality.

<p>Sub-group analyses of 28-day mortality.</p